40 |
KliniskBiokemi i Norden · 2 2014
10. Ben-Dov IZ, Galitzer H, Lavi-Moshayoff V,
Goetz R, Kuro-oM, Mohammadi M, et al.
The parathyroid is a target organ for FGF23
in rats. J Clin Invest 2007;117:4003-8.
11. Faul C, Amaral AP, Oskouei B, Hu MC,
Sloan A, Isakova T, et al. FGF23 induces
left ventricular hypertrophy. J Clin Invest
2011;121:4393-408.
12. Yamazaki Y1, Okazaki R, ShibataM, Hase-
gawa Y, Satoh K, Tajima T, et al. Increased
circulatory level of biologically active full-
length FGF-23 in patients with hypop-
hosphatemic rickets/osteomalacia. J Clin
EndocrinolMetab 2002;87:4957-60.
13. Shimada T, Mizutani S, Muto T, Yoneya T,
HinoR, TakedaS, et al.Cloningand charac-
terization of FGF23 as a causative factor of
tumorinducedosteomalacia. ProcNatlAcad
Sci USA, 2001;98:6500-5.
14. Benet-Pagès A, Orlik P, StromTM, Lorenz-
Depiereux B. An FGF23 missense muta-
tion causes familial tumoral calcinosis
with hyperphosphatemia. HumMol Genet
2005;14:385-90.
15. MeguidElNahasA, BelloAK. Chronic kid-
ney disease: the global challenge. Lancet,
2005;365:331-40.
16. BlockGA, KlassenPS, Lazarus JM,Ofsthun
N, Lowrie EG, ChertowGM.Mineralmeta-
bolism, mortality, and morbidity in main-
tenance hemodialysis. J Am Soc Nephrol
2004;15:2208-18.
17. KohN, Fujimori T,Nishiguchi S, Tamori A,
Shiomi S,NakataniT, et al. Severely reduced
productionof klotho inhumanchronic renal
failure kidney. Biochem Biophys Res Com-
mun, 2001;280:1015-20.
18. OlausonH, LarssonTE. FGF23 andKlotho
in chronickidneydisease.CurrOpinNeph-
rol Hypertens 2013; 22:397-404.
19. Gutiérrez OM, Mannstadt M, Isakova T,
Rauh-Hain JA, Tamez H, Shah A, et al.
Fibroblast growth factor 23 and mortality
among patients undergoing hemodialysis.
NEngl JMed 2008;359:584-92.
20. IsakovaT1,XieH,YangW,XieD,Anderson
AH, Scialla J, et al. Fibroblast growth fac-
tor 23 and risks of mortality and end-stage
renal disease inpatientswithchronickidney
disease. JAMA 2011;305:2432-9.
21. Ix JH, Katz R, Kestenbaum BR, de Boer
IH, ChoncholM, Mukamal KJ, et al. Fibro-
blast growth factor-23 and death, heart
failure, and cardiovascular events in com-
munity-living individuals: CHS (Cardio-
vascular Health Study). J Am Coll Cardiol
2012;60:200-7.
22. Shimada T, Urakawa I, Isakova T, Yama-
zaki Y, Epstein M, Wesseling-Perry K, et
al. Circulating fibroblast growth factor 23
in patients with end-stage renal disease
treated by peritoneal dialysis is intact and
biologically active. JClinEndocrinolMetab
2010;95:578-85.
23. Larsson T, Yu X, Davis SI, Draman MS,
Mooney SD, CullenMJ,White KE. A novel
recessivemutation in fibroblast growth fac-
tor-23 causes familial tumoral calcinosis. J
ClinEndocrinolMetab 2005;90:2424-7.
Kabbleka (Caltha palustris) Foto: HenrikAlfthan.
